miR-1-3p targets GLIS1 to reverse epithelial-mesenchymal transition (EMT) and inhibit invasion and metastasis in breast cancer
This study demonstrates that miR-1-3p suppresses breast cancer invasion and metastasis by directly targeting GLIS1 to inhibit the GLIS1/β-catenin axis, thereby reversing epithelial-mesenchymal transition (EMT).
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Breast cancer is a disease where cells in the breast grow out of control, but the most dangerous aspect is not the initial growth; it is the ability of those cells to spread, or metastasize, to other parts of the body. This spread often happens because cancer cells undergo a transformation called the epithelial-mesenchymal transition. In simple terms, this is a process where cells that usually stick tightly together in a structured tissue lose their bonds, become more mobile, and gain the ability to invade new areas. To stop this spread, scientists look for the molecular switches that control this transition. One such switch is a tiny piece of genetic material called a microRNA, which acts like a dimmer switch for other genes, turning their activity down. Another key player is a protein called GLIS1, which functions as a master regulator, telling cells how to behave. Understanding how these two interact could reveal new ways to keep cancer cells from moving and spreading.
A team of researchers from hospitals in Ningxia, China, has uncovered a specific chain of events that drives this dangerous spread in breast cancer. They discovered that a protective molecule, known as miR-1-3p, is missing in breast cancer tumors. When this molecule is present, it acts as a brake on a protein called GLIS1. In healthy tissue, miR-1-3p keeps GLIS1 levels low, but in breast cancer, the lack of miR-1-3p allows GLIS1 to build up. This excess GLIS1 then triggers a cascade that makes cancer cells slippery and mobile, allowing them to break away and travel to other organs. The researchers found that by restoring the missing miR-1-3p, they could turn the tables, forcing the cancer cells to stop moving and stick together again.
To reach this conclusion, the scientists first looked at real-world data. They examined tissue samples from 60 female patients who had undergone surgery for breast cancer. By comparing the cancer tissue to the healthy tissue next to it, they confirmed that the protective miR-1-3p was significantly lower in the cancer samples. The less of this molecule they found, the more advanced the cancer appeared to be. They also tested this in the lab using breast cancer cells that are known for being very aggressive. When they forced these cells to produce more miR-1-3p, the cells stopped growing as fast and lost their ability to crawl through barriers, a key step in spreading.
The team then asked a crucial question: how does miR-1-3p do this? They used computer models to predict which gene miR-1-3p might be targeting and found a strong match with the gene for GLIS1. To prove this connection, they performed a direct test where they mixed the miR-1-3p with the GLIS1 gene in a dish. The results showed that miR-1-3p physically binds to GLIS1 and shuts it down. When the researchers increased miR-1-3p, the levels of GLIS1 protein dropped. Conversely, when they removed GLIS1 from the cancer cells, the cells behaved more like normal, stationary cells, losing their ability to invade and migrate. This confirmed that GLIS1 is the direct target that miR-1-3p uses to control the cancer's behavior.
The study went deeper to understand the mechanism behind this control. They found that GLIS1 works by activating a specific signaling pathway involving a protein called beta-catenin. When GLIS1 is high, it pushes beta-catenin to turn on genes that make cells mobile and less sticky. The researchers observed that when miR-1-3p was added back into the cancer cells, it lowered GLIS1, which in turn lowered beta-catenin. This change caused the cells to switch back to a stationary state, producing more of a "glue" protein called E-cadherin and less of the "loose" proteins that allow movement. To be certain this was the correct path, they performed rescue experiments. They added extra GLIS1 to the cells that already had high levels of miR-1-3p. This extra GLIS1 successfully overpowered the miR-1-3p, causing the cells to become mobile again. This proved that miR-1-3p works specifically by suppressing GLIS1.
Finally, the researchers tested these findings in living animals to see if the results held up in a complex biological system. They injected breast cancer cells into the underarm area of mice. One group of mice received cells that had been engineered to produce high levels of miR-1-3p, while the control group received normal cells. Over three weeks, the tumors in the control group grew large and spread. In contrast, the tumors in the mice with the extra miR-1-3p remained small and showed clear boundaries, with very little invasion into the surrounding tissue. The tumors were also significantly lighter in weight. These results confirmed that the molecular mechanism observed in the lab works effectively inside a living body.
This research provides a clear map of a specific pathway that breast cancer uses to spread. It shows that the loss of miR-1-3p is a critical event that allows the GLIS1 protein to rise and trigger the epithelial-mesenchymal transition. By identifying this chain of events, the study suggests that therapies designed to restore miR-1-3p or block GLIS1 could potentially stop cancer cells from becoming mobile and spreading. While the study does not claim to have a cure, it offers a precise target for future treatments, moving the focus from general chemotherapy to specific molecular interventions that could prevent metastasis.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.